Stay updated on Cabozantinib in HR+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in HR+ Breast Cancer Clinical Trial page.

Latest updates to the Cabozantinib in HR+ Breast Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page now shows a 403 Forbidden error. The previously visible study record for NCT01441947 is no longer accessible on this ClinicalTrials.gov page.SummaryDifference19%

- Check12 days agoChange DetectedThe page displays Revision: v3.7.0 instead of v3.6.6, indicating a minor update to the page template or content management system. This change does not alter the study details or results on the page.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page revision label was updated from v3.6.5 to v3.6.6. This appears to be a minor metadata update and does not modify the study information presented on the page.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page shows a new revision indicator: v3.6.5, replacing v3.6.4. This reflects an update to the page build rather than any changes to the study content.SummaryDifference0.1%

- Check62 days agoChange DetectedThe page's revision label was updated to v3.6.4, signaling a newer revision of the page. This appears to be a maintenance update rather than a substantive change to study information.SummaryDifference0.1%

- Check83 days agoChange DetectedA new page revision label, v3.6.3, was added and the previous label v3.6.2 was removed. This indicates an update to the page's versioning, without changes to the study text or data presented.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib in HR+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in HR+ Breast Cancer Clinical Trial page.